Introduction
Multiple myeloma (MM) remains an incurable disease characterized by recurrent remissions and relapses. Up until recent years, the treatment goals have largely been palliative, except for patients eligible for high-dose therapy plus auto-SCT (HDT/auto-SCT). As the OS is a reflection of not just the remission duration after induction therapy, but also remission durations after sequential salvage therapies, the effect of the quality of induction response on the OS has remained controversial. As a result, the significance of achieving CR rather than PR or stable disease after induction on the long-term outcome has been hotly debated. However, for transplant-eligible patients and those presenting with gene expression profiling-defined high-risk features, recent data have shown that the frontline treatment goal after HDT/auto-SCT should shift toward achieving a CR. [1] [2] [3] [4] [5] [6] [7] [8] [9] Sustainment of CR for at least 3 years from treatment initiation has also been shown to be especially important for patients presenting with high-risk disease. 10 Of late, the introduction of novel combinations entailing immunomodulatory agents such as thalidomide (THAL) or lenalidomide, together with bortezomib or melphalan for induction treatment, has resulted in superior CR rates that are comparable with those obtained with HDT/auto-SCT.
11-13 It remains to be observed whether better treatment responses obtained with these novel agents translate to better long-term survival outcomes, and whether further intensive therapy will benefit patients already in CR. 14, 15 As CR remains relatively rare even in the patients who have received HDT/auto-SCT, and that very good partial response (VGPR) has been shown to be a robust prognostic indicator of longer OS in the IFM99 (Intergroupe Francophone du Myelome 99) trials for transplanted patients, the prognostic value of achieving VGPR or better (XVGPR) in both the transplant and non-transplant settings will be explored in this study. 1, 16 Our results show that the degree of eventual response, as defined by the attainment of at least a very good partial response, represented the most important early surrogate marker for better survival.
Patients and methods

Patients
We identified 179 consecutive and previously untreated MM patients with complete treatment data who presented to our institution from January 2001 to December 2007 for this retrospective analysis. Patient characteristics were evaluated before treatment by history, physical examination, laboratory evaluation and BM examination. Information obtained included age, gender, complete blood count, serum albumin level, b 2 -microglobulin level, BM plasma cells count and the metaphase cytogenetics result. Interphase FISH for high-risk cytogenetics was only introduced to our institution in 2004, and hence the results of FISH will not be considered in this analysis because of inadequate data. Every patient was staged by the International Staging System (ISS). Information on induction treatment and HDT/auto-SCT was reviewed. Table 1 summarizes the clinical characteristics of the patients by their transplant status.
Patients who received HDT/auto-SCT consolidation (n ¼ 57) after induction treatment were significantly younger. There were significantly fewer patients with ISS III disease at diagnosis in the transplant group. To date, 72 patients (43%) have died, and the median follow-up time is 3.3 years. Median PFS and OS from diagnosis were 2.6 (95% confidence interval (CI) 2.1-3.1) and 5.6 (95% CI, 4.4-6.8) years, respectively.
Authorization to carry out this retrospective analysis was approved by our institutional review board.
Metaphase cytogenetics BM specimens were cultured in RPMI-1640 medium and stimulated with IL-6, and harvested after 72 h of incubation. Trypsin Giemsa banding was performed according to standard protocols. At least 20 metaphases were analyzed from the BM cultures. Analysis of the metaphase cytogenetics for risk stratification was based on the DNA ploidy status, which could be further divided into three distinct groups: normal diploid karyotype, hyperdiploid karyotype (number of chromosomes from 48 to 74) and nonhyperdiploid karyotype that encompasses hypodiploidy, pseudodiploidy and near-tetraploidy. Although certain recurrent genetic changes such as t(4;14), t(14;16), chromosome 13q deletion and loss of 17p13 on metaphase cytogenetics have been recognized to be prognostic, the number of patients detected with these individual aberrations are too small for a meaningful analysis and hence are not considered in our study. In contrast, stratifying the karyotype by the ploidy status allows better discrimination of the prognosis. The yield with metaphase cytogenetics is not high (46% in our series), with 54% of cases showing a normal diploid karyotype that, in all likelihood, could originate from dividing normal hematopoietic cells. Hence, these results will not be included in the survival analysis as the cytogenetic risk of such patients may not be evaluable. 18 A total of 12 patients who received MP alone as primary treatment were excluded from the analysis. Bortezomib became available for induction treatment of patients with high-risk disease from 2005. 19, 20 As all patients were unselected and the choice of induction treatment was at the discretion of individual treating physicians, no meaningful analysis on the relative efficacy of the different primary induction treatments can be made.
Patients younger than 65 years old were eligible for HDT/auto-SCT entailing PBSC support after high-dose melphalan conditioning. 21 As an institutional policy, HDT/ auto-SCT is performed immediately (within 6 months) after completion of induction treatment. The median time between the start of initial treatment to HDT/auto-SCT for transplanted patients was 8.5 months (range 4-21 months). As the 1-year landmark analysis will be used for subsequent comparison of survival outcomes, seven patients who received HDT/auto-SCT after 1 year from initial treatment were excluded from the transplant group in this study, and their responses achieved before the 1-year landmark was considered as the eventual induction response with standard therapy.
Response and progression criteria and end points Disease response was assessed after induction treatment for all patients and after transplantation for those who received HDT/auto-SCT. This was assessed by serum and urine protein electrophoresis, and immunofixation. As most patients were treated outside clinical trials, it was not This will encompass patients with CR or VGPR (defined as having serum and urine M-protein detectable by immunofixation, but not on electrophoresis or X90% reduction in serum M-protein plus urine M-protein level of o100 mg per 24 h). PR is defined as a reduction in serum M-protein by 450% and reduction in 24-h urinary M-protein by 490% or to o200 mg per 24 h. PFS was measured from start of treatment to date of progression, relapse or death. Patients with stable disease (N ¼ 34) or progressive disease (N ¼ 11) while undergoing initial treatment will be grouped as nonresponders in the survival analysis. Patients who had not experienced progressive disease or relapse were censored on the last date that they were known to be alive and event free. OS was calculated from the start of treatment to the date of death or last follow-up visit. Death from all causes was included.
Statistical methods
Descriptive statistics, including median and range, were used to summarize patient characteristics. The w 2 and Fisher's exact two-sided tests were used for comparisons between categorical variables and the t-test was used for continuous variables. Survival curves were estimated using the Kaplan-Meier method. 23 Patient characteristics were evaluated in univariate analyses to identify significant prognostic factors for the OS. The Kaplan-Meier curves were compared for statistical differences by using the logrank test in the univariate analyses. 24 The P-values of o0.05 were considered to reflect statistical significance.
To correctly assess the effect of XVGPR achievement, and to avoid the biases related with the time necessary to achieve XVGPR, landmark analysis at 1 year was used for comparing survival outcomes of the different response groups. 25 In this analysis, only patients with at least 12 months of follow-up were included, and the subsequent survival times after 12 months of follow-up were compared. In all, 18 patients were excluded from the 1-year landmark analyses, as 6 patients were censored whereas 12 patients died within the 1-year landmark time. Of these patients, 13 had no response to treatment, whereas 3 had PR and 2 achieved XVGPR. Only 1 patient received HDT/auto-SCT.
We applied multivariate Cox's regression modeling to determine what baseline parameters, along with the eventual induction response, significantly affected the OS. 26 
Results
Response
The response rate with primary induction treatment alone for all patients was 69%, including 29% XVGPR. A majority of the transplanted patients received VCR, adriamycin and DEXregimen as the initial therapy, whereas the majority of non-transplanted patients received novel therapies, including THAL/DEX, MPT or bortezomibbased regimes. After HDT/auto-SCT, the XVGPR rate for transplanted patients increased from 31% after primary induction treatment to 65%. The eventual response rate for all patients was 72%, with the XVGPR rate increasing to 41%. The XVGPR rate was significantly lower among patients with a non-hyperdiploid karyotype. There was no correlation between age at diagnosis and the ISS stage with the likelihood of response.
Survival
The corresponding 1-year landmark OS for transplanted patients was significantly longer at 7.7 years (95% CI 3.6-11.7) when compared with non-transplanted patients at 4.4 years (95% CI 2.5-6.3; Figure 1a) . Overall, the ISS was discriminating of survival outcomes, with patients of ISS I, VGPR after induction treatment for longer survival in MM D Tan et al II and III having median OS from 1-year landmark of 6.5 (95% CI 3.5-9.4), 4.7 (95% CI 2.3-6.9) and 3.7 (95% CI 1.8-4.5) years, respectively (Figure 1b) . Similarly, by classifying conventional metaphase cytogenetic findings into risk groups based on the DNA ploidy status, distinct risk categories could be appreciated. The median 1-year landmark OS for patients with hyperdiploid and nonhyperdiploid karyotypes were 3.6 (95% CI 1.9-4.7) and 1.8 (95% CI 1.2-2.3) years, respectively (Figure 1c) . Patients with normal diploid karyotype were found to have a more superior median OS at 8.7 years (95% CI 5.1-12.3). As the karyotyping results of these patients may not be representative of the MM clone, they are deemed not comparable with the other abnormalities, and hence excluded from further survival analysis. Only metaphase cytogenetics and not the ISS predicted for the PFS and the induction response.
The 1-year landmark OS for patients who achieved XVGPR and PR, and those who had no response were 8.1 (95% CI 3.2-13.0), 4.6 (95% CI 3.2-6.0) and 2.3 (95% CI 0.1-4.7) years, respectively (P ¼ 0.001; Figure 2a) . Patients who obtained XVGPR enjoyed a significantly longer median PFS at 3.0 years when compared with the other response groups (Figure 2b ). Among patients who attained the eventual response of XVGPR, there was no significant difference in the PFS or OS between those who were transplanted and those who were not.
On multivariate analysis of the OS at the landmark time of 1 year, the attainment of XVGPR emerged as the single most significant prognostic indicator, overriding all other clinical and laboratory parameters in predicting a more favorable survival outcome ( Table 2 ).
Discussion
The importance of attaining a CR may have been overlooked in the past when MM was deemed incurable and a palliative approach was accepted as a standard of care. The importance of CR only came to light after the introduction of HDT/auto-SCT when CR rate increased significantly from o10% with conventional chemotherapy to 430%.
14 These studies with HDT/auto-SCT were the first to show the survival benefits associated with achievement of a CR. Consequently, auto-SCT/HDT became established as the major part of the standard frontline therapy in younger patients. 6 The IFM99 investigators have recently validated the effect of achieving XVGPR as a robust prognostic indicator, as CR remains a less common occurrence even in the transplant setting. 16 To date, the prognostic effect of achieving CR or VGPR has only been discussed in the context of HDT/auto-SCT. The introduction of novel agents in combination with MP or with DEX has resulted in higher CR and VGPR rates that are comparable with those observed with HDT/auto-SCT. 12 Hence, it is now possible to analyze the effect of XVGPR in the non-transplant setting.
Our study involving unselected patients with diverse backgrounds and different induction therapies, along with several other prospective studies on selected patients who were uniformly treated, have shown the significance of attaining a CR or VGPR on the survival outcomes. 5, 6, 27, 28 We have confirmed the prognostic effect of attaining XVGPR in both the transplant and non-transplant settings. We also show that the superior PFS accorded by achieving XVGPR was able to translate to a longer OS.
As XVGPR encompasses CR, VGPR and near-CR, the limitation of this study is hence the inability to discriminate patients who attained CR from those with VGPR or near CR. This is important as several recent studies have shown significantly longer survival with CR (negative immunofixation and o5% plasma cells in the BM marrow) than 27, 29, 30 it was shown that survivals with VGPR and near-CR were similar to those with PR. Hence, the achievement of CR represents the best early outcome of treatment, and the attainment of XVGPR signifies a transitional phase in this direction. Thus, immunofixation and BM studies to distinguish CR from VGPR are strongly recommended for all patients who have attained XVGPR, and such testings should be monitored serially while in CR.
Continuous efforts are being made to improve the sensitivity of methods used for CR assessment, including molecular techniques and immunophenotyping assays. The combination of effective agents for induction, together with novel post-HDT/auto-SCT consolidation/maintenance therapies, have already been reported to induce cytogenetic or even molecular remissions that seem to be critical for long-term survival. 31, 32 The quality and definition of CR will most likely undergo further revisions. Prospective trials will answer the questions of whether attainment of a stringent CR will be superior to CR, and whether molecular CR will be even better. As XVGPR will encompass a greater proportion of patients, it is hence a simple and robust indicator applicable to more patients, and will represent the first therapeutic milestone to be strived for before other more stringent remissions are to be achieved.
Our study also supports the role of early HDT/SCT in MM, as the frequency of XVGPR doubled from approximately 30 to 60% after subsequent intensive therapy, and this incremental improvement of depth of response is associated with improved PFS and OS. Hence, eligible patients should be considered for early intensive therapy at diagnosis to provide a better chance for conversion from non-response or PR to XVGPR or even CR. More patients would then have a better opportunity for long survival.
Metaphase cytogenetics-defined high-risk status was associated with a lower XVGPR rate in our study. This finding corroborates the study by Harousseau et al. 33 in which the bortezomib/DEX combination was not able to improve upon the poor CR rate in patients with poor-risk cytogenetics. Some recent studies suggested that the prognostic effect of CR achievement might not be pertinent in certain subtypes of MM, such as those with a preexisting monoclonal gammopathy of unknown significance, or those with adverse genetic risk, such as t(4;14). However, from a practical standpoint, it is still reasonable to aim for XVGPR for all patients, as the newer novel agents are now better tolerated and less toxic than previous myelosuppressive therapies. 34, 35 Although metaphase cytogenetics still serves as a valuable prognostic tool for the long-term prognosis on univariate analysis, the multivariate analysis showed that XVGPR outweighed this feature. The lower yield on metaphase cytogenetics may limit its prognostic power. It remains to be observed whether incorporation of the more sensitive FISH analysis will further improve the predictive value of the underlying cytogenetics in a multivariate analysis.
The controversial issue on the role of HDT/auto-SCT in the era of novel therapeutics has remained unanswered at the present moment. In the Eastern Cooperative Oncology Group E4A03 trial, patients who continued primary lenalidomide and DEX combination beyond four cycles and did not receive transplants had a similar 2-year OS as those patients who received SCTs. 36 Similarly, our study shows that there is no significant difference in PFS or OS in those who attained XVGPR, whether this was achieved by HDT/auto-SCT or primary induction therapy alone. This was despite our transplant cohort being younger and showing lower incidence of ISS III disease. Our study is the first to show the unifying favorable prognosis conferred by attaining XVGPR in a pool of patients with diverse background characteristics, and regardless of the transplant status. A randomized trial re-exploring the role of HDT/ auto-SCT in the context of novel therapies is urgently needed to provide the answer on the role of HDT/auto-SCT in the current era of novel therapies. 37, 29 
